AVDL (avadel.com) יחס שווי פעילות להכנסות

לוגו של חברה ציבורית Avadel Pharmaceuticals plc (AVDL)

Avadel Pharmaceuticals generates revenue through the exclusive distribution of LUMRYZ for the treatment of narcolepsy. High customer retention is driven by a unique dosing regimen approved by the FDA. The EV-to-revenue ratio on the GURU.Markets chart demonstrates the fundamental value of the assets, where 8299.61 characterizes this valuation parameter. High profitability with a minimal workforce is achieved through a proprietary slow-release formula.

AVDL מכפיל EV/Sales avadel.com (23.11.2025 - 28.02.2026)

AVDL (Avadel Pharma): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- ציטוטים נוכחיים ותחזית שווי ממוצעת:
- מדדי הערכת שווי שוק של העסק:
הערכת שווי פונדמנטלית:avadel.com AVDL
מוצר עיקרי של Avadel Pharmaceuticals PLC

Efficient logistics for sleep medications at Avadel Pharmaceuticals (AVDL) directly impact the EV/Sales ratio dynamics. This metric compares the total enterprise value of the business to annual revenue, excluding the influence of debt load. The calculation combines market capitalization and net debt, divided by revenue. Aggressive growth in this indicator may mask fundamental risks of asset overvaluation. Investors should be wary of false optimism when the chart shows sharp deviations from industry averages.